Compare MGIH & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MGIH | SNGX |
|---|---|---|
| Founded | 1978 | 1987 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Publishing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.4M | 14.4M |
| IPO Year | 2023 | 1987 |
| Metric | MGIH | SNGX |
|---|---|---|
| Price | $1.42 | $1.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 55.6K | ★ 181.8K |
| Earning Date | 10-28-2025 | 03-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $25,334,149.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.11 | $1.02 |
| 52 Week High | $4.84 | $6.23 |
| Indicator | MGIH | SNGX |
|---|---|---|
| Relative Strength Index (RSI) | 55.59 | 35.32 |
| Support Level | $1.41 | $1.04 |
| Resistance Level | $1.61 | $1.16 |
| Average True Range (ATR) | 0.12 | 0.08 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 34.15 | 17.95 |
Millennium Group International Holdings Ltd supplies paper-based packaging solutions, including inner packaging boxes produced with offset or flexo printing and outer corrugated boxes used for transportation, storage, pallets, and point-of-purchase displays. The company manufactures corrugated products of different sizes, shapes, thicknesses, and strengths according to customer specifications. It also operates a supply chain management business in Vietnam to service international clients who source their packaging needs from Vietnam and other ASEAN countries. The corrugated paper is durable, versatile, economical, and lightweight.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).